RecruitingPhase 1NCT06992661

A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease

Studying Interstitial lung disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Intervention
RJ026 inhaled powder(drug)
Enrollment
84 target
Eligibility
40 years · All sexes
Timeline
20262026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06992661 on ClinicalTrials.gov

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

See all trials for Interstitial lung disease

← Back to all trials